Drug intelligence / Profile preview

ABS-005

Development stage: Preclinical
Lead developer: Alpha Biomedical
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

ABS-005 is an investigational Chimeric Antigen Receptor T-cell (CAR-T) therapy being developed by Alpha Biomedical for the treatment of solid tumors. Currently in the research stage, this cell-based immunotherapy involves engineering T cells to express a chimeric antigen receptor designed to recognize and attack malignant cells within solid tumor environments. While the specific molecular target has not been disclosed, the program represents Alpha Biomedical's expansion into CAR-T technologies for oncology indications beyond hematological malignancies.

Beyond the preview

Go deeper on ABS-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABS-005.

Explore the full profile